These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 20008772

  • 21. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
    Bonomo RA, Rudin SA, Shlaes DM.
    FEMS Microbiol Lett; 1997 Mar 01; 148(1):59-62. PubMed ID: 9066111
    [Abstract] [Full Text] [Related]

  • 22. Penicillin sulfone inhibitors of class D beta-lactamases.
    Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA.
    Antimicrob Agents Chemother; 2010 Apr 01; 54(4):1414-24. PubMed ID: 20086146
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria.
    Danishuddin M, Khan A, Faheem M, Kalaiarasan P, Hassan Baig M, Subbarao N, Khan AU.
    J Biomol Struct Dyn; 2014 Apr 01; 32(5):741-50. PubMed ID: 23600675
    [Abstract] [Full Text] [Related]

  • 26. Aspartic acid for asparagine substitution at position 276 reduces susceptibility to mechanism-based inhibitors in SHV-1 and SHV-5 beta-lactamases.
    Giakkoupi P, Tzelepi E, Legakis NJ, Tzouvelekis LS.
    J Antimicrob Chemother; 1999 Jan 01; 43(1):23-9. PubMed ID: 10381097
    [Abstract] [Full Text] [Related]

  • 27. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F.
    J Biol Chem; 2005 Oct 14; 280(41):34900-7. PubMed ID: 16055923
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate.
    Mehta SC, Furey IM, Pemberton OA, Boragine DM, Chen Y, Palzkill T.
    J Biol Chem; 2021 Oct 14; 296():100155. PubMed ID: 33273017
    [Abstract] [Full Text] [Related]

  • 30. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
    Barnes MD, Taracila MA, Rutter JD, Bethel CR, Galdadas I, Hujer AM, Caselli E, Prati F, Dekker JP, Papp-Wallace KM, Haider S, Bonomo RA.
    mBio; 2018 Dec 11; 9(6):. PubMed ID: 30538183
    [Abstract] [Full Text] [Related]

  • 31. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ, Jin YF, Turner HL.
    J Antimicrob Chemother; 1993 Jan 11; 31(1):89-103. PubMed ID: 8383105
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
    Pagan-Rodriguez D, Zhou X, Simmons R, Bethel CR, Hujer AM, Helfand MS, Jin Z, Guo B, Anderson VE, Ng LM, Bonomo RA.
    J Biol Chem; 2004 May 07; 279(19):19494-501. PubMed ID: 14757767
    [Abstract] [Full Text] [Related]

  • 34. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans.
    Nukaga M, Yoon MJ, Taracilia MA, Hoshino T, Becka SA, Zeiser ET, Johnson JR, Papp-Wallace KM.
    ACS Infect Dis; 2021 Apr 09; 7(4):826-837. PubMed ID: 33723985
    [Abstract] [Full Text] [Related]

  • 35. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR.
    Biochemistry; 2007 Aug 07; 46(31):8980-7. PubMed ID: 17630699
    [Abstract] [Full Text] [Related]

  • 36. The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.
    Drawz SM, Bethel CR, Hujer KM, Hurless KN, Distler AM, Caselli E, Prati F, Bonomo RA.
    Biochemistry; 2009 Jun 02; 48(21):4557-66. PubMed ID: 19351161
    [Abstract] [Full Text] [Related]

  • 37. New Conformations of Acylation Adducts of Inhibitors of β-Lactamase from Mycobacterium tuberculosis.
    Tassoni R, Blok A, Pannu NS, Ubbink M.
    Biochemistry; 2019 Feb 19; 58(7):997-1009. PubMed ID: 30632739
    [Abstract] [Full Text] [Related]

  • 38. Crystal Structures of KPC-2 and SHV-1 β-Lactamases in Complex with the Boronic Acid Transition State Analog S02030.
    Nguyen NQ, Krishnan NP, Rojas LJ, Prati F, Caselli E, Romagnoli C, Bonomo RA, van den Akker F.
    Antimicrob Agents Chemother; 2016 Jan 04; 60(3):1760-6. PubMed ID: 26729491
    [Abstract] [Full Text] [Related]

  • 39. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb 04; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 40. Biochemical characterization of CTX-M-15 from Enterobacter cloacae and designing a novel non-β-lactam-β-lactamase inhibitor.
    Faheem M, Rehman MT, Danishuddin M, Khan AU.
    PLoS One; 2013 Feb 04; 8(2):e56926. PubMed ID: 23437273
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.